Abstract
The last decade has witnessed an expanding interest in the concept of early intervention (El) in psychotic disorders, notably schizophrenia. This is supported by the well-established association between prolonged untreated illness duration and poor outcome, as well as some evidence of progressive neurobiological changes in the early course of schizophrenia, both in the prepsychotic and psychotic phases as evidenced by brain imaging studies in schizophrenia. Increasingly, mental health service systems around the world have been incorporating specialized El programs. Controlled effectiveness studies in recent years have yielded encouraging data. Several questions in regard to the timing, choice of interventions, and the populations most likely to benefit from Els still remain. More evidence-based data are needed to place the El models in schizophrenia on firm footing in order to effectively implement them in the resource-strapped community mental health service settings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Perkins DO, Gu H, Boteva K, et al.: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162:1785–1804.
Marshall M, Lewis S, Lockwood A, et al.: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005, 62:975–983.
Thompson PM, Vidal C, Giedd JN, et al.: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001, 98:11650–11655.
Pantelis C, Velakoulis D, McGorry PD, et al.: Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281–288.
Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991, 17:325–351.
Yung AR, Phillips LJ, McGorry PD: Treating Schizophrenia in the Prodromal Stage. London: Taylor & Francis; 2004.
Yung AR, Yuen HP, Berger G, et al.: Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007 [Epub ahead of print].
Pukrop R, Schultze-Lutter F, Ruhrmann S, et al.: Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first-and multiple-episode schizophrenia. J Clin Exp Neuropsychol 2006, 28:1388–1407.
McGorry PD, Hickie IB, Yung AR, et al.: Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006, 40:616–622.
Keefe RS, Seidman LJ, Christensen BK, et al.: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004, 161:985–995.
McGorry PD, Yung AR, Phillips LJ, et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59:921–928.
McGlashan TH, Zipursky RB, Perkins D, et al.: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006, 163:790–799.
Nordentoft M, Thorup A, Petersen L, et al.: Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006, 83:29–40.
Morrison AP, French P, Walford L, et al.: Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004, 185:291–297.
Cornblatt BA, Lencz T, Kane JM: Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001, 51:31–38.
Ohlsen RI, O’Toole MS, Purvis RG, et al.: Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004, 14(Suppl 4):S445–S451.
Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209–1223.
Jones PB, Barnes TR, Davies L, et al.: Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079–1087.
Hogarty GE, Flesher S, Ulrich R, et al.: Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004, 61:866–876.
Petersen L, Jeppesen P, Thorup A, et al.: A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005, 331:602.
Linszen D, Dingemans P, Lenior M: Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res 2001, 51:55–61.
Marshall M, Rathbone J: Early intervention for psychosis. Cochrane Database Syst Rev 2006, 4:CD004718.
Blyler CR: Commentary: Service system perspectives on early intervention research. Schizophr Bull 2003, 29:867–875.
Pelosi AJ, Birchwood M: Is early intervention for psychosis a waste of valuable resources? Br J Psychiatry 2003, 182:196–198.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keshavan, M.S., Amirsadri, A. Early intervention in schizophrenia: Current and future perspectives. Curr Psychiatry Rep 9, 325–328 (2007). https://doi.org/10.1007/s11920-007-0040-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-007-0040-8